RxDoctor Payments Data

Dalia Abou Zeki, MD

Neurology · Charlotte, NCNPI 1730542606

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.3%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Genentech USA, Inc. at 55.4% of the total. Reporting peaked in 2022 at $6,220 and has fallen 66.1% since, to $2,105 in 2025.

$15,555in general payments, 2019–2025

Across 96 payments — averaging $162.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$9K
  • EMD Serono, Inc.$3K
  • Amgen$2K
  • ANI Pharmaceuticals, Inc.$313
  • Eisai Inc.$234
  • Mallinckrodt Hospital Products Inc.$218
  • plus $1K from 19 others
$43,954in research payments, 2019–2025

Across 11 payments — averaging $3995.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$42K
  • Roche Products Limited$2K

What the payments were for

  • Consulting fees$9,23059%
  • Speaking & faculty fees$2,25014%
  • Travel & lodging$7255%
  • Food & beverage$3,25021%
  • Education$1001%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,555 in reported general payments places this provider in the 80th percentile of 566 neurology providers in North Carolina.

See all neurology providers in North Carolina →

Medicare billing

Part B allowed, 2024
$42,957
Medicare patients
160
Services billed
304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Carbidopa-LevodopaCarbidopa/Levodopa72$940
Levetiracetam12$612
Oxcarbazepine30$602
Clonazepam18$301
Gabapentin31$299
Phenobarbital15$277
Pregabalin15$158
Baclofen14$129
Primidone12$116
Carbidopa-Levodopa ErCarbidopa/Levodopa13$85

Paid to pharmacies, not to this prescriber.

Other neurology in Charlotte

See the full list for North Carolina →

Where these figures come from

Is this you, or does something look wrong? →